Programmed Death‐Ligand 1 Expression and Tumor‐Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma

Objectives/Hypothesis The tumor immune microenvironment in temporal bone squamous cell carcinoma (TBSCC), including the programmed death‐ligand 1 (PD‐L1) expression and tumor‐infiltrating lymphocytes (TILs), has not been established. Study Design Retrospective cohort study. Methods We performed immu...

Full description

Saved in:
Bibliographic Details
Published in:The Laryngoscope 2021-12, Vol.131 (12), p.2674-2683
Main Authors: Hongo, Takahiro, Kuga, Ryosuke, Miyazaki, Masaru, Komune, Noritaka, Nakano, Takafumi, Yamamoto, Hidetaka, Koike, Kensuke, Sato, Kuniaki, Kogo, Ryunosuke, Nabeshima, Kazuki, Oda, Yoshinao, Nakagawa, Takashi
Format: Article
Language:English
Subjects:
Bone cancer
Laryngoscopy
Ligands
Lymphocytes
Medical prognosis
programmed death‐ligand 1
Squamous cell carcinoma
Temporal bone
tumor microenvironment
tumor‐infiltrating lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives/Hypothesis The tumor immune microenvironment in temporal bone squamous cell carcinoma (TBSCC), including the programmed death‐ligand 1 (PD‐L1) expression and tumor‐infiltrating lymphocytes (TILs), has not been established. Study Design Retrospective cohort study. Methods We performed immunohistochemistry analyses to retrospectively analyze 123 TBSCC cases for PD‐L1 expression and TILs and their prognostic significance. We also evaluated the prognostic correlations between these immunomarkers and the therapeutic responses to chemoradiotherapy (CRT). Results PD‐L1 expression (≥1%) was detected in 62 (50.4%) TBSCC cases and was significantly associated with worse prognosis: progression‐free survival (PFS), P 
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.29689